Asco 2022 – Merus gets some competition
Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Asco 2021 – Merus’s slight improvement might not win over investors
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.